The short answer
Two systematic reviews with meta-analysis published in 2025 assessed GLP-1 receptor agonists in children and adolescents: Kotecha and colleagues in JAMA Pediatrics and Sedenho-Prado and colleagues in the International Journal of Obesity.
Key facts
- Kotecha 2025
- JAMA Pediatr, 1 December (PMID 40952752)
- Sedenho-Prado 2025
- Int J Obes, August (PMID 40269110)
- Design
- Systematic review and meta-analysis
- Populations
- Children and adolescents
- Landmark trial
- STEP TEENS, NEJM 2022
- Still absent
- Long-term follow-up data
Why review-level evidence appeared when it did
Systematic reviews require a body of primary studies to review. Two independent meta-analyses appearing in 2025 indicates enough paediatric trials had accumulated to make pooling worthwhile, which is itself a statement about how quickly this field moved after the adult approvals.
What a meta-analysis adds over individual trials
Precision and breadth. Pooling across studies narrows confidence intervals and can detect adverse events too infrequent to appear reliably in any single trial. It also assesses the quality of the underlying evidence, which individual papers do not do for themselves.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it cannot add
Duration. A meta-analysis of 68-week trials produces a more precise estimate of what happens over 68 weeks; it cannot say anything about year five. Pooling more short studies never becomes a long study, and that is the specific limitation that matters most for a population who may be treated for decades.
The two reviews cover different ground
Kotecha and colleagues addressed efficacy and safety in children and adolescents with obesity or type 2 diabetes in JAMA Pediatrics. Sedenho-Prado and colleagues addressed metabolic outcomes and safety in children and adolescents with obesity in the International Journal of Obesity. Overlapping but distinct questions, published independently in the same year.
Where the underlying trials sit
STEP TEENS remains the landmark, with 201 randomised adolescents over 68 weeks. Tirzepatide's adolescent Phase 3, NCT06075667, reached primary completion in June 2026 with 160 participants aged 12 to 17. The evidence base is real and it is young.
The boundary this site maintains
Everything described concerns licensed medicines and registered trials in paediatric populations, conducted under clinical supervision with ethics approval and specialist oversight. Nothing supplied here is any of those compounds, is an alternative to them, or has any place in the care of a child.
Frequently asked questions
Is there systematic review evidence in children?
Yes. Two independent systematic reviews with meta-analysis were published in 2025, in JAMA Pediatrics and the International Journal of Obesity.
Does pooling trials tell us about long-term effects?
No. Pooling 68-week trials gives a more precise estimate of 68 weeks. It never becomes a long-term study.
What is the landmark paediatric trial?
STEP TEENS, published in NEJM in December 2022, with 201 randomised adolescents over 68 weeks.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKotecha P et al., Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis. JAMA Pediatr 2025 (PMID 40952752)pubmed.ncbi.nlm.nih.gov
- PubMedSedenho-Prado LG et al., Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity. Int J Obes 2025 (PMID 40269110)pubmed.ncbi.nlm.nih.gov
- PubMedWeghuber D et al., Once-Weekly Semaglutide in Adolescents with Obesity. NEJM 2022 (PMID 36322838)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Tirzepatide in adolescents (NCT06075667)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD - and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management - which is the finding.